Clinical-stage biopharmaceutical company focused on developing therapies for cancer.
Syndax Pharmaceuticals, Inc., headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for the treatment of cancer. At the forefront of its pipeline are SNDX-5613 and SNDX-6352 (axatilimab), promising candidates targeting critical oncological challenges.
SNDX-5613 is currently undergoing phase 1/2 clinical trials, focusing on inhibiting the interaction between Menin and mixed lineage leukemia 1 protein, addressing MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Meanwhile, SNDX-6352, a monoclonal antibody, blocks the colony stimulating factor 1 (CSF-1) receptor, offering potential treatment for patients grappling with chronic graft versus host disease (cGVHD).
In addition to its primary candidates, Syndax Pharmaceuticals continues to develop Entinostat, reinforcing its commitment to enhancing therapeutic options through comprehensive research and development efforts. The company maintains strategic collaborations, including partnerships with the National Cancer Institute and the Eastern Cooperative Oncology Group, underscoring its collaborative approach to advancing oncology treatments.
Founded in 2005, Syndax Pharmaceuticals has established itself as a pivotal player in oncology research, leveraging strategic alliances and licensing agreements with industry leaders such as Kyowa Hakko Kirin Co., Ltd. The company’s dedication to addressing unmet medical needs in cancer treatment underscores its mission to deliver meaningful advancements that improve patient outcomes globally.